Abbott Laboratories Return on Tangible Equity 2010-2025 | ABT
Current and historical return on tangible equity values for Abbott Laboratories (ABT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Abbott Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-06-30 | $13.98B | $20.96B | 82.76% |
| 2025-03-31 | $13.50B | $19.44B | 98.14% |
| 2024-12-31 | $13.40B | $18.15B | 124.81% |
| 2024-09-30 | $5.77B | $9.02B | 74.08% |
| 2024-06-30 | $5.56B | $8.43B | 81.55% |
| 2024-03-31 | $5.63B | $7.36B | 97.30% |
| 2023-12-31 | $5.72B | $6.33B | 114.01% |
| 2023-09-30 | $5.16B | $5.14B | 118.68% |
| 2023-06-30 | $5.16B | $4.31B | 137.51% |
| 2023-03-31 | $5.80B | $4.30B | 177.48% |
| 2022-12-31 | $6.93B | $3.65B | 307.89% |
| 2022-09-30 | $7.89B | $2.75B | 583.40% |
| 2022-06-30 | $8.55B | $2.38B | 4987.76% |
| 2022-03-31 | $7.73B | $0.23B | -639.62% |
| 2021-12-31 | $7.07B | $0.05B | -320.21% |
| 2021-09-30 | $7.24B | $-1.97B | -201.05% |
| 2021-06-30 | $6.38B | $-3.14B | -131.53% |
| 2021-03-31 | $5.72B | $-3.78B | -94.14% |
| 2020-12-31 | $4.50B | $-5.53B | -61.35% |
| 2020-09-30 | $3.38B | $-6.95B | -41.37% |
| 2020-06-30 | $3.11B | $-8.07B | -36.33% |
| 2020-03-31 | $3.58B | $-8.77B | -40.10% |
| 2019-12-31 | $3.69B | $-8.92B | -39.34% |
| 2019-09-30 | $3.29B | $-8.49B | -32.88% |
| 2019-06-30 | $2.90B | $-9.53B | -26.59% |
| 2019-03-31 | $2.62B | $-10.55B | -22.29% |
| 2018-12-31 | $2.37B | $-11.47B | -18.92% |
| 2018-09-30 | $0.89B | $-12.00B | -6.69% |
| 2018-06-30 | $0.93B | $-13.02B | -7.50% |
| 2018-03-31 | $0.48B | $-13.57B | -4.20% |
| 2017-12-31 | $0.48B | $-14.40B | -4.65% |
| 2017-09-30 | $2.10B | $-8.43B | -46.38% |
| 2017-06-30 | $1.17B | $-9.00B | -359.48% |
| 2017-03-31 | $1.50B | $-9.21B | 44.78% |
| 2016-12-31 | $1.40B | $8.50B | 19.83% |
| 2016-09-30 | $1.37B | $8.41B | 21.16% |
| 2016-06-30 | $2.28B | $5.73B | 39.46% |
| 2016-03-31 | $2.45B | $5.61B | 39.46% |
| 2015-12-31 | $4.42B | $6.13B | 69.79% |
| 2015-09-30 | $4.56B | $5.63B | 74.17% |
| 2015-06-30 | $4.52B | $7.45B | 70.00% |
| 2015-03-31 | $4.20B | $6.15B | 62.46% |
| 2014-12-31 | $2.28B | $5.37B | 31.67% |
| 2014-09-30 | $1.97B | $6.85B | 23.70% |
| 2014-06-30 | $2.40B | $8.53B | 27.78% |
| 2014-03-31 | $2.41B | $8.10B | 28.81% |
| 2013-12-31 | $2.58B | $9.76B | 31.68% |
| 2013-09-30 | $3.04B | $8.14B | 48.21% |
| 2013-06-30 | $4.02B | $7.43B | 82.32% |
| 2013-03-31 | $5.27B | $7.20B | 170.94% |
| 2012-12-31 | $5.96B | $2.45B | 480.21% |
| 2012-09-30 | $6.53B | $2.44B | 1938.83% |
| 2012-06-30 | $4.89B | $0.23B | -571.14% |
| 2012-03-31 | $5.11B | $-0.15B | -359.46% |
| 2011-12-31 | $4.73B | $-1.17B | -196.08% |
| 2011-09-30 | $4.55B | $-2.34B | -131.96% |
| 2011-06-30 | $5.14B | $-2.03B | -111.53% |
| 2011-03-31 | $4.49B | $-4.12B | -85.92% |
| 2010-12-31 | $4.63B | $-5.32B | -86.34% |
| 2010-09-30 | $4.73B | $-6.97B | -152.11% |
| 2010-06-30 | $5.31B | $-4.49B | -839.83% |
| 2010-03-31 | $5.31B | $-4.66B | 579.54% |
| 2009-12-31 | $5.75B | $3.70B | 267.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $230.506B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $157.140B | 37.47 |
| Stryker (SYK) | United States | $149.815B | 30.50 |
| EssilorLuxottica (ESLOY) | France | $148.753B | 0.00 |
| Medtronic (MDT) | Ireland | $119.490B | 16.86 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.052B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.480B | 25.41 |
| ResMed (RMD) | United States | $42.323B | 30.27 |
| Agilent Technologies (A) | United States | $33.835B | 22.06 |
| GE HealthCare Technologies (GEHC) | United States | $33.726B | 15.85 |
| Terumo (TRUMY) | Japan | $27.731B | 32.86 |
| Koninklijke Philips (PHG) | Netherlands | $26.731B | 17.68 |
| Insulet (PODD) | United States | $23.441B | 78.54 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.941B | 13.33 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.385B | 0.00 |
| Baxter (BAX) | United States | $12.466B | 9.63 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.798B | 28.64 |
| Lantheus Holdings (LNTH) | United States | $3.817B | 10.32 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.443B | 24.09 |
| Perrigo (PRGO) | Ireland | $3.255B | 8.13 |
| Prestige Consumer Healthcare (PBH) | United States | $3.201B | 14.20 |
| ICU Medical (ICUI) | United States | $3.045B | 20.73 |
| Haemonetics (HAE) | United States | $2.623B | 11.71 |
| LeMaitre Vascular (LMAT) | United States | $2.189B | 46.95 |
| AtriCure (ATRC) | United States | $1.793B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.789B | 11.26 |
| Curaleaf Holdings (CURLF) | Canada | $1.750B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.687B | 72.46 |
| AdaptHealth (AHCO) | United States | $1.262B | 17.94 |
| Phibro Animal Health (PAHC) | United States | $1.262B | 16.14 |
| Acuren (TIC) | United States | $1.220B | 0.00 |
| Neogen (NEOG) | United States | $1.210B | 19.21 |
| BioLife Solutions (BLFS) | United States | $1.196B | 2496.00 |
| Tilray Brands (TLRY) | Canada | $1.167B | 0.00 |
| Valneva SE (VALN) | France | $0.979B | 0.00 |
| InMode (INMD) | Israel | $0.897B | 8.30 |
| Kestra Medical Technologies (KMTS) | United States | $0.852B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.626B | 0.00 |
| SNDL (SNDL) | Canada | $0.581B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.557B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.535B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.61 |
| Surmodics (SRDX) | United States | $0.528B | 0.00 |
| Evolus (EOLS) | United States | $0.468B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.466B | 16.04 |
| CeriBell (CBLL) | United States | $0.425B | 0.00 |
| Owens & Minor (OMI) | United States | $0.412B | 3.66 |
| Sanuwave Health (SNWV) | United States | $0.338B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.328B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.303B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.290B | 0.00 |
| Omeros (OMER) | United States | $0.285B | 0.00 |
| Brainsway (BWAY) | Israel | $0.279B | 56.81 |
| Sanara MedTech (SMTI) | United States | $0.274B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.266B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 20.18 |
| High Tide (HITI) | Canada | $0.250B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Quanterix (QTRX) | United States | $0.228B | 0.00 |
| Cerus (CERS) | United States | $0.222B | 0.00 |
| Exagen (XGN) | United States | $0.217B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.212B | 0.00 |
| Organigram Global (OGI) | Canada | $0.201B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.185B | 15.47 |
| FitLife Brands (FTLF) | United States | $0.157B | 19.34 |
| Biote (BTMD) | United States | $0.147B | 4.87 |
| Jushi Holdings (JUSHF) | United States | $0.125B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.098B | 0.00 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.10 |
| Jin Medical (ZJYL) | China | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.077B | 0.00 |
| Safety Shot (SHOT) | United States | $0.070B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 31.80 |
| Veru (VERU) | United States | $0.052B | 0.00 |
| Zynex (ZYXI) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 34.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.21 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.031B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |